Widely Used Birth Control Comes With Brain-shaped Asterisk

Vial of Depo-Provera and syringe on medical tray

Per the CDC, roughly 1 in 4 sexually active American women have used the form of birth control Depo-Provera. Studies, though, found that the effects of this injectable go beyond contraception. The government paper trail also keeps growing, regarding the risks it may cause.  A JAMA Neurology study found a 2.43-fold higher risk for developing a brain tumor among users. Just this month, on July 2, 2026, another JAMA study flagged the injection as having the strongest risk of brain tumor development of any contraceptive. (This study also reported reassuring news: risk fades within roughly five years of stopping. Additionally, absolute risk stays low, as less than 5 in 10,000 women have this extremely negative effect.)

According to the Mayo Clinic, “Depo-Provera is a birth control shot that has the hormone progestin.” In actuality, it injects medroxyprogesterone acetate, a synthetic version of the natural hormone progesterone.  Long-term use of this injection can result in meningiomas, which are usually benign brain tumors. Meningiomas, though, can crowd the brain, triggering headaches, vision loss, and seizures. In December 2025, the U.S. Food and Drug Administration ordered a warning on the Depo-Provera label.

Meanwhile, Pfizer reached a June 2026 settlement covering over 5,500 federal lawsuits alleging it downplayed the danger. Though this number may seem large, the percent of Depo-Provera users it represents is small. So, users shouldn’t panic but should talk to their doctor about duration of use.

Women With Brain Injuries Less Likely to Reach Trauma Centers – But the Full Picture Matters

Male patient with head injury eating with visitor and female patient with head injury writing

A major new study published June 15, 2026, in the Canadian Medical Association Journal (CMAJ), and found in the PubMed database, reveals a striking inequity: women hospitalized with traumatic brain injury (TBI) in Ontario are significantly less likely than men to be admitted to specialized (Level I or II) trauma centers. After adjusting for age, injury severity, comorbidities, and income, women’s odds for prompt treatment remain 26% lower (OR 0.74) than that of men.

The finding echoes earlier work: a 2022 US study found that female trauma patients, including those with TBI, experienced longer delays to reach trauma care than men even after accounting for injury severity and type. An accompanying editorial was pointedly titled “Sex Disparities in Trauma Care -Why Are the Women Waiting?” Other U.S. research similarly documents women being undertriaged in emergency departments despite comparable injuries.

Yet context is essential. Per CDC data reported in 2018 and 2020, males were nearly two times more likely to be hospitalized for a TBI (79.9 age-adjusted rate versus 43.7) and three times more likely to die from one than females (28.3 versus 8.4). Even in the Ontario study, men had more severe head trauma (33% vs 25%). The disparity in care is real and demands attention, but men remain more likely to sustain, and die from, TBI overall.